-
Posted by
Two Blokes Apr 16 -
Filed in
Stock
-
5 views
Teladoc Health, Inc.'s stock has declined significantly, from a high of $14 per share in February to $7 per share, with ongoing financial struggles and underperformance in key segments. The company reported a net loss of $1 billion in 2024, with declining revenues in its BetterHelp segment and minimal growth in Integrated Care. Despite efforts to cut costs and new initiatives like the Catapult Health acquisition and a partnership with Eli Lilly, Teladoc's value proposition remains unclear.
